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Type 2 diabetes is highly prevalent and is the major cause
of progressive chronic kidney disease in American Indians.
Genome-wide association studies identified several loci
associated with diabetes but their impact on susceptibility
to diabetic complications is unknown. We studied the
association of 18 type 2 diabetes genome-wide association
single-nucleotide polymorphisms (SNPs) with estimated
glomerular filtration rate (eGFR; MDRD equation) and urine
albumin-to-creatinine ratio in 6958 Strong Heart Study family
and cohort participants. Center-specific residuals of eGFR and
log urine albumin-to-creatinine ratio, obtained from linear
regression models adjusted for age, sex, and body mass
index, were regressed onto SNP dosage using variance
component models in family data and linear regression in
unrelated individuals. Estimates were then combined across
centers. Four diabetic loci were associated with eGFR and one
locus with urine albumin-to-creatinine ratio. A SNP in the
WFS1 gene (rs10010131) was associated with higher eGFR in
younger individuals and with increased albuminuria. SNPs in
the FTO, KCNJ11, and TCF7L2 genes were associated with
lower eGFR, but not albuminuria, and were not significant in
prospective analyses. Our findings suggest a shared genetic
risk for type 2 diabetes and its kidney complications, and a
potential role for WFS1 in early-onset diabetic nephropathy
in American Indian populations.
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American Indians have a high prevalence of obesity, type 2
diabetes (T2D), and metabolic syndrome.1,2 These conditions,
together with hypertension, hyperlipidemia,3,4 and smok-
ing,5,6 may contribute to an increased burden of chronic
kidney disease (CKD), defined either by increased albumi-
nuria or by decreased glomerular filtration rate (GFR).7–9
CKD is associated with increased cardiovascular disease events
and death in American Indians.10,11 Therefore, understanding
the pathways leading to CKD is relevant to public health.
T2D is one of the most common conditions associated
with CKD and kidney failure in Western populations.12
Diabetic nephropathy most typically progresses through an
early phase in which microalbuminuria, detected by a spot
urine albumin-to-creatinine ratio (UACR) X30mg/g, is
associated with supranormal GFR, i.e., glomerular hyperfil-
tration.13–15 These initial abnormalities may be reversible, but
then may progress to macroalbuminuria (UACRX300mg/g)
and an irreversible decline in GFR. Alternatively, in some T2D
individuals, impaired GFR can occur without substantial
albuminuria.16 In the Strong Heart Study (SHS), American
Indians with T2D often have microalbuminuria or macro-
albuminuria associated with decreased GFR.17 Similarly,
young Pima Indians with T2D, aged 5–19 years, frequently
have microalbuminuria, which is a strong predictor of
macroalbuminuria at follow-up.18
Diabetic nephropathy occurs more often among family
members,19 suggesting a genetic susceptibility to this
complication. The heritability of kidney traits in American
Indians has been documented for estimated GFR (eGFR) and
UACR, a marker of kidney damage.20–23 Genome-wide
association studies have identified several loci associated with
T2D (reviewed in Wolfs et al.24). There is some evidence for
associations of T2D loci with diabetic nephropathy including
reported variants in PPARG in Chinese25 and KCNQ1 in
Japanese individuals.26 In addition, TCF7L2 has been
associated with diabetic nephropathy in individuals with
early-onset T2D27 and among middle-aged individuals.28
Given the large number of newly identified loci for T2D, the
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effects of genes associated with T2D on kidney function and
damage merit exploration in American Indian populations.
We recently genotyped several genome-wide association
study-validated single-nucleotide polymorphisms (SNPs) in
American Indians in the Genetic Epidemiology of Causal
Variants Across the Life Course (CALiCo) Consortium as
part of the Population Architecture using Genomics and
Epidemiology study.29 We studied associations of T2D SNPs
with prevalent eGFR and UACR in over 6900 American
Indians from the Strong Heart Family Study (SHFS) and SHS
cohort. We also explored the evidence for SNP associations
with incident CKD and new-onset microalbuminuria using
longitudinal data from the SHS participants.
RESULTS
Baseline characteristics of the SHFS and SHS cohort
American Indian samples are displayed in Table 1. By design,
the mean age of SHFS participants was lower than that of the
SHS cohort participants. The prevalence of T2D and
impaired fasting glucose varied across centers, but the mean
body mass index (BMI) was similar when comparing the
cohort with family members for the same recruiting center.
Cohort participants had lower mean eGFR and higher
median UACR than family study participants. A total of 18
SNPs representing 15 loci were examined. Minor allele
frequencies per center are shown in Supplementary Table S1
online. Two SNPs in each of the FTO and the TCF7L2 genes
were highly correlated in American Indians (r240.95 in the
overall sample and within each center).
Cross-sectional associations with eGFR and UACR in
SHS and SHFS
We identified significant associations of SNPs in FTO, TCF7L2,
and KCNJ11 with eGFR (Po0.003; Table 2). The FTO
rs8050136 A allele and TCF7L2 rs7901695 C allele (both
associated with increased risk of T2D) were associated with a
0.08 and 0.09 reduction of eGFR residuals per allele copy,
respectively. The KCNJ11 rs5219 T allele, previously associated
with increased T2D risk, was associated with 0.05 reductions
in eGFR residuals per allele copy. We also identified nominal
associations of WFS1 with eGFR and UACR. The WFS1
rs10010131 G allele was associated with increased eGFR and
UACR, but we noted a significant between study heterogeneity
for the association with eGFR (P for heterogeneity¼ 0.07). In
center-specific analyses, we noted the lowest P-values in
analyses of the SHFS compared with the older (445 years)
SHS participants (Table 2 footnote). We thus hypothesized
age-specific effects on eGFR. We then performed analyses
using age categories (o45, 45 to 59 and 60 years or more).
The magnitude of effect ofWFS1 rs10010131 G allele on eGFR
was larger in American Indians o45 years old (P¼ 0.0003)
compared with those 45 to 59 orX60 years old, in whom the
SNP effect was greatly attenuated (Figure 1, Supplementary
Table S2 online, P for heterogeneity¼ 0.05, I2¼ 67.5%).
Table 1 | Baseline characteristics of American Indians of the Strong Heart Family Study (1998–2003) and Strong Heart Study
(1989–1991)
Strong Heart Family Study Strong Heart Study
Dakota Arizona Oklahoma Dakota Arizona Oklahoma
Number 1176 1165 1167 1188 1147 1115
Mean age (s.d.), years 38.4 (16.8) 36.2 (15.5) 43.4 (17.3) 56.3 (8.1) 55.8 (7.9) 56.8 (8.4)
Female sex, % 58.7 62.1 59.3 56.8 63.8 57.9
Type 2 diabetes, % 13.4 31.4 19.8 33.1 63.7 36.1
Impaired fasting glucose, % 7.9 8.1 6.2 14.7 10.7 14.5
Mean BMI (s.d.), kg/m2 30.1 (6.8) 35.5 (8.8) 31.1 (6.9) 29.3 (5.5) 32.5 (7.1) 30.7 (6.0)
Mean eGFR (s.d.), ml/min per 1.73 m2a 96.6 (23.8) 114.5 (28.9) 93.6 (22.9) 81.3 (20.3) 86.1 (23.6) 78.6 (17.5)
Median UACR (25–75%), mg/g 7.1 (1.7–7805.9) 10.4 (1.7–9756.1) 7.1 (1.1–9645.7) 7.5 (0.1–7493) 27.1 (0.1–65,000.0) 8.5 (0.04–12,419.8)
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio.
aeGFR was estimated using the Modified Diet and Renal Disease equation.
Table 2 |Meta-analyses findings for type 2 diabetes–SNP associations for eGFR and log UACR residuals
Trait SNP Loci/gene
Coded
allele Other allele b s.e. P-value Number
P-value
for heterogeneity
Direction of
effect for coded allele
eGFR rs8050136a FTO A C 0.078 0.0253 0.002 6835 0.13 mBMI and T2D
rs9939609a FTO A T 0.0751 0.0252 0.003 6802 0.18 mBMI and T2D
rs5219 KCNJ11 T C 0.0543 0.0178 0.002 6807 0.91 mT2D
rs7901695a TCF7L2 C T 0.0884 0.0265 0.0008 6834 0.24 mT2D
rs7903146a TCF7L2 T C 0.0758 0.0269 0.005 6837 0.17 mT2D
rs10010131b WFS1 G A 0.0704 0.0252 0.005 6837 0.07 mT2D
UACR rs10010131 WFS1 G A 0.0684 0.0263 0.009 6784 0.34 mT2D
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; log UACR, urine albumin-to-creatinine ratio; SNP, single nucleotide polymorphism; T2D, type
2 diabetes.
aFTO variants (rs8050136 and rs9939609) and TCF7L2 variants (rs7901695 and rs7903146) are in linkage disequilibrium: r240.95 in the overall sample and within each center.
bEstimates for the family study are: b (s.e.)¼ 0.12 (0.04), P¼ 0.0008, and for cohort study b (s.e.)¼0.02 (0.04), P¼ 0.63.
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To examine whether the significant findings were medi-
ated by diabetes, we also performed diabetes-stratified analyses
(Supplementary Table S3 online) and analyses adjusting for
T2D. Interestingly, TCF7L2 SNP association with eGFR was
unchanged when adjusting for T2D. The overall T2D-adjusted
associations of WFS1 (P¼ 0.08), KCNJ11 (P¼ 0.72), and
FTO (P¼ 0.03) with eGFR were no longer significant, but the
age-specific association with eGFR for the WFS1 SNP was
mostly unchanged (P¼ 0.0003 to 0.0008, n¼ 2249, for asso-
ciation among individuals 45 years or younger). The association
of rs10010131 with UACR was no longer significant when
adjusting for T2D.
Longitudinal associations with CKD and microalbuminuria
in the SHS cohort
In prospective data of SHS participants, incident (stage 3) CKD
events were defined by the new occurrence of an eGFR of 60ml/
min per 1.73m2 or lower, or by self-report of maintenance
dialysis or kidney transplantation among individuals with an
eGFR460ml/min per 1.73m2 at baseline visit. Approximately
477 CKD events occurred among 3160 individuals at a median
follow-up of 8 years. Of the 3918 SHS participants with baseline
eGFR X60ml/min per 1.73m2, 1035 with albuminuria at
baseline were excluded for the analysis of incident albuminuria
(B499 events). A FTO SNP (rs9939609) was significantly asso-
ciated with incident CKD in the Dakotas but not in the analyses
of all three centers (Supplementary Table S4 online), and none
of the loci was associated with new-onset microalbuminuria
(Supplementary Table S5 online). However, the direction of the
effect of the association with microalbuminuria was consistent
with the findings for continuous prevalent UACR.
DISCUSSION
CKD affects minorities disproportionally, who also progress
more often to end-stage renal disease than individuals
of European ancestry.8,9 American Indians have a high
prevalence of obesity and T2D, which contribute to the large
burden of cardiovascular and kidney diseases in this
population.7–9,30 We investigated the genetic contribution of
recently discovered T2D genetic variants to kidney function
and markers of kidney damage in American Indians. The
selected SNPs were initially identified in European and Asian
ancestry studies, and some of these variants have also been
replicated for T2D associations in American Indian partici-
pants of the SHS (Haiman et al., Diabetes, in press). Several
loci (FTO, KCNJ11, TCF7L2, andWFS1) were associated with
eGFR, and a SNP in WFS1 was associated with albuminuria.
WFS1 product is a transmembrane protein localized to the
endoplasmic reticulum,31 which is involved in endoplasmic
reticulum stress signaling pathways.32 The WFS1 SNP T2D
risk allele was associated with increased albuminuria and
eGFR, with a large effect on eGFR in American Indians
younger than 45 years compared with those 45 to 59 years old
or older than 60 years, for whom the SNP effect was greatly
attenuated. In analyses adjusted for both BMI and T2D, the
association with eGFR was slightly changed in the younger
age category and it was no longer significant for UACR. These
are interesting findings as American Indians develop diabetic
nephropathy at earlier ages than individuals of other ancestry.33
Early stages in the pathogenesis of the diabetic nephropathy
are characterized by microalbuminuria and hyperfiltration.
Our findings of increasing eGFR and albuminuria for WFS1,
although modest, are consistent with the early development
of nephropathy and suggest that the genetic effect is partially
mediated by diabetes. These findings will require further
confirmation in American Indians and other populations,
and in studies using direct measures of kidney function to
detect higher ranges of GFR.
In contrast, the alleles associated with T2D risk for FTO,
KCNJ11, and TCF7L2 were associated with reduced eGFR in
American Indians and were not associated with albuminuria.
FTO is known to confer risk for T2D through its association
with obesity34 in both children and adults.34,35 Variants in
this gene have been recently reported to be associated with
end-stage renal disease in two case–control studies.36 It is
interesting to note that the associations with low eGFR in
American Indians occurred in models adjusting for BMI,
suggesting an effect independent of body size, although the
mean BMI in American Indians in our study was high and in
the range of overweight to obese. The KCNJ11 gene was
identified in T2D associations in individuals of European and
Asian ancestry.37–39 The gene product impairs glucose-induced
insulin release, and its variants has also been associated with
increased BMI.40,41 It is intriguing that variants in both these
genes are associated with lower eGFR in the context of
obesity, which is a risk factor for CKD.42 However, for both
genes, the associations seem to be mediated by diabetes, as
they are no longer significant in analyses adjusted for T2D.
TCF7L2 has shown consistent associations with T2D across
ancestry groups43,44 and, in American Indians, it has been
associated with glucose homeostasis traits (unpublished data).
TCF7L2 product is a key component of the Wnt signaling
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Figure 1 |Age-specific effects of WFS1 rs1001013 G allele on
estimated glomerular filtration rate (eGFR) residuals.
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pathway involved in the regulation of pancreatic b-cell
proliferation, differentiation, and insulin secretion,45 but is
also important in kidney embryogenesis and disease.46 The
rs7903146 T allele was significantly associated with lower
eGFR in American Indians but not with incident CKD, which
is in contrast to a previous report in a population-based study
of middle-aged individuals.28 Interestingly, a recent large
study of T2D showed association of the rs7903146 T allele
with diabetic nephropathy, with larger effect in individuals
with early-onset T2D.27 In our study, this genetic variant
shows no evidence of heterogeneity across age categories. In
addition, the association was slightly attenuated when
adjusting for diabetes. In summary, our findings suggest that
at least four T2D loci are associated with kidney traits in
American Indians, of which two may have effects that are
partially independent of diabetes. These findings may have
important implications in prevention efforts for CKD in this
population.
Our prospective associations with incident CKD and new-
onset albuminuria were restricted to the SHS cohort study,
which has long-term longitudinal data. Although we
noted significant associations for the FTO rs9939609 A allele
in the Dakotas, our samples were limited. In addition, we
did not identify associations with new-onset albuminuria for
tested SNPs.
This study used kidney function estimates from an
equation derived from CKD individuals. Calibrated serum
creatinine concentrations are currently not available in the
SHS. The SNPs investigated were identified in individuals of
European ancestry. However, the FTO, WFS1, and TCF7L2
SNP associations have been replicated in American Indians
for T2D or glycemic traits.
In summary, we identified four T2D loci associated with
kidney function in American Indians, including two
previously reported associations with kidney traits in
individuals of European ancestry. The WFS1 variant was
associated with increased albuminuria and eGFR, and it
showed age-specific effects on eGFR. These findings suggest
shared genetic risk factors for T2D and its kidney complica-
tions in this population.
MATERIALS AND METHODS
Population and phenotypes
The SHS is a population-based cohort study funded by the National
Heart, Lung, and Blood Institute (NHLBI) of 4549 American Indian
men and women, aged 45–74 years and recruited from 13 tribes
located in Arizona, North and South Dakota, and Oklahoma, who
underwent a baseline (1989–1991) and then two follow-up
(1993–1995 and 1996–1999) examinations.47 The SHFS started in
1998 to study the genetics of cardiovascular disease among
American Indian populations, and it recruited family members
from the original cohort study.48 Over 3600 American Indians aged
14–93 years and in 94 multigenerational families were examined, of
whom 540 also are SHS cohort members (and were included in the
family data only for analyses). The SHS and SHFS protocols were
approved by the Indian Health Service Institutional Review Board,
by the Institutional Review Boards of the participating Institutions,
and by the Indian tribes participating in these studies.47,48 All
participants gave informed consent for genetic testing.
Demographic data and medical history were obtained by means
of a personal interview during a clinical examination. Anthropo-
metric measures of body weight (kg) and height (m) were used to
estimate BMI (kg/m2). Blood was collected after an overnight fast,
and plasma or serum samples were stored at 80 1C until analyzed.
T2D was defined as a fasting blood glucose level of 126mg/dl or
higher, history of diabetes, or the use of diabetic medications.49
Impaired fasting glucose and impaired glucose tolerance were
defined by the World Health Organization criteria based on fasting
plasma glucose and 75 g oral glucose tolerance test results. Serum
and urine creatinine were assayed by a kinetic alkaline picrate
method and urine albumin by a sensitive nephelometric method,
both on the Hitachi 717 platform (Roche Diagnostics, Indianapolis,
IN). Urine albumin excretion was estimated as the UACR (mg/g),
and eGFR was calculated using the Modified Diet and Renal Disease
(MDRD) equation.50
In prospective data of SHS participants, incident (stage 3) CKD
events were defined by the new occurrence of an eGFR of 60ml/min
per 1.73m2 or lower, or by self-report of maintenance dialysis or
kidney transplantation. CKD events included events that occurred
during a median of 8 years follow-up between the baseline and
visit 3 examinations in individuals without a prior history
of CKD (n¼ 516 with CKD at baseline were excluded). New-
onset albuminuria was defined as follows: 1. UACR X30mg/g at
follow-up among individuals with UACRo30mg/g at baseline, or as
2. UACR X30mg/g at follow-up among individuals with UACR
o30mg/g at baseline, and with a baseline eGFR X60ml/min per
1.73m2. Of 4549 SHS participants, 1035 with albuminuria at baseline
were excluded for the analysis of incident albuminuria by definition 1.
Of 3918 SHS participants with baseline eGFR X60ml/min per
1.73m2, 1313 with albuminuria at baseline were excluded for the
incident albuminuria defined by definition 2. Because results were
unchanged using definition 1 or 2, we reported only findings using
definition 1.
SNP selection, genotyping, and quality control
SNPs were selected from T2D genome-wide association study
publications before January 2009, and our analysis is thus restricted
to these loci. Genotyping was performed at the University of Texas
Health Science Center, Houston, using Taqman assays (Applied
Biosystems, Carlsbad, CA). Replica samples were included as controls.
Quality control performed included sample call rates (495%), con-
cordance of blinded replicates (498%), and deviation from Hardy–
Weinberg equilibrium among founders (Po0.01). Individuals with
more than 10% of missing genotypes (n¼ 64) were excluded.
Eighteen SNPs on 15 loci passed quality control and were included
in these analyses (Supplementary Table S1 online). SNPs that failed
genotyping were rs4430796 (HNF1b), rs2074196 (KCNQ1), and
rs1326634 (SLC30A8). We estimated the linkage disequilibrium
between SNPs in the same loci using Haploview.
Statistical analysis
Cross-sectional analyses. Quantitative traits with non-normal
distribution were natural log-transformed for analysis. We obtained
center-specific residuals of eGFR and log UACR (LACR) using linear
regression models adjusted for age, age2, sex, age and sex interactions,
and BMI. These residuals were then regressed onto SNP dosage using
variance component models for family data to account for family
relatedness and population history51 and by using linear regression
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for analysis of unrelated individuals (SHS). For SHS analyses, we also
adjusted for self-reported blood quantum to account for ancestry. To
account for age-specific effects, analyses were performed within
categories of age (o45, 45 to 59, and 60 years or older). We
performed a quantitative transmission disequilibrium test52 in the
SHFS and found no evidence of population substructure within
centers but significant evidence of population stratification when
combining centers. Therefore, analyses were stratified by center.
Summary estimates were combined across age categories and
centers using a weighted average of point estimate meta-analyses. We
also tested for evidence of between-study heterogeneity53 for age and
center estimates by estimating the between-study variance and the I2
metric, which is a measure of the percentage of the total variation
across strata due to heterogeneity rather than chance.54 Unadjusted
P-values are reported. A Bonferroni correction for multiple testing
P¼ 0.003 (a¼ 0.05/15 independent tests) was considered significant.
In sensitivity analyses, we excluded 333 individuals younger than 18
years of age (ranging from 15 to 17 years) from eGFR analyses, and
age-specific results were unchanged. We also performed analyses
adjusting for T2D and stratified analyses by diabetes.
Longitudinal analyses. For significant SNP associations in
cross-sectional analysis, we evaluated associations with incident
CKD and increased albuminuria in the SHS using center-stratified
logistic regression models adjusted for age, age2, sex, and BMI. Odds
ratio and 95% confidence intervals are reported. A Bonferroni
correction for multiple testing P¼ 0.01 (a¼ 0.05/4 independent
tests) was considered significant.
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